RxDoctor Payments Data

Jason Haviza, NP

Gerontology · Indianapolis, INNPI 1891346763

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.5% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Abbott at 45.4% of the total. Reporting peaked in 2021 at $602 and has fallen 55.8% since, to $266 in 2025.

$1,235in general payments, 2019–2025

Across 43 payments — averaging $28.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$561
  • Pfizer$141
  • Novartis$88
  • Alnylam Pharmaceuticals Inc.$71
  • Novo Nordisk$69
  • AstraZeneca$66
  • plus $238 from 7 others

What the payments were for

  • Travel & lodging$1058%
  • Food & beverage$1,13092%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,235 in reported general payments places this provider in the 75th percentile of 230 gerontology providers in Indiana.

See all gerontology providers in Indiana

Medicare billing

Part B allowed, 2024
$24,739
Medicare patients
100
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan157$204,093
JardianceEmpagliflozin99$129,983
EliquisApixaban69$103,866
FarxigaDapagliflozin Propanediol83$89,164
OzempicSemaglutide14$26,457
XareltoRivaroxaban15$18,137
Torsemide211$7,998
Potassium Chloride140$4,307
Spironolactone202$1,925
Atorvastatin Calcium187$1,787
Eplerenone12$1,474
Metoprolol Succinate136$1,225
Carvedilol113$1,118
Ezetimibe14$913
Hydralazine Hcl28$910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$88$204,093157 claims
PfizerEliquis$141$103,86669 claims
AstraZenecaFarxiga$66$89,16483 claims
Novo NordiskOzempic$69$26,45714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 230 gerontology providers in Indiana.

Other gerontology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →